Evidence map›Paper›PMID 33601392›Full record

ReviewNephron2021

The COVID-Kidney Controversy: Can SARS-CoV-2 Cause Direct Renal Infection?

Wei Ling Lau, Jonathan E Zuckerman, Ajay Gupta, Kamyar Kalantar-Zadeh

Open access · bronzeAbstract readReview
In one paragraph

Review in Nephron, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. The COVID-19 Patient in the Surgical Intensive Care Unit.The Surgical clinics of North America · 2022
    Review
  6. Article
  7. [Kidney damage in COVID-19].Nephrologie & therapeutique · 2021
    Article
  8. Distinctive features of severe SARS-CoV-2 pneumonia.The Journal of clinical investigation · 2021
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wei Ling LauDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California, USA.
Jonathan E ZuckermanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA.
Ajay GuptaDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California, USA.
Kamyar Kalantar-ZadehDivision of Nephrology, Hypertension and Kidney Transplantation, University of California Irvine School of Medicine, Orange, California, USA, kkz@uci.edu.
University of California, Irvine · USUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextDetermining whether SARS-CoV-2 causes direct infection of the kidneys is challenging due to limitations in imaging and molecular tools. Subject of Review: A growing number of conflicting kidney biopsy and autopsy reports highlight this controversial issue. Second Opinion: Based on the collective evidence, therapies that improve hemodynamic stability and oxygenation, or dampen complement activation, are likely to ameliorate acute kidney injury in COVID-19. At this time, whether inhibition of viral infection and replication directly modulates kidney damage is inconclusive.

Indexed as

Acute Kidney InjuryAutopsyBiopsyCOVID-19HumansKidneyKidney DiseasesNephritis, InterstitialCOVID-19ImmunohistochemistryKidney pathologyRibonucleic acidSARS-CoV-2

Identifiers

PMID33601392
PMCPMC8018211
OpenAlexW3132770927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.